Studies on Agents with Vasodilator and β-Blocking Activities. II

Toshimi SEKI; Takayuki TAKEZAKI; Rikio OHUCHI; Hiroshi OHUYABU; Yoshitaka TANIMOTO; Takashi YAMAGUCHI; Norinobu SAITOH; Tsutomu ISHIMORI; Kikuo YASUDA

doi:10.1248/cpb.43.247

Toshimi SEKI, Takayuki TAKEZAKI, Rikio OHUCHI, Hiroshi OHUYABU, Yoshitaka TANIMOTO, Takashi YAMAGUCHI, Norinobu SAITOH, Tsutomu ISHIMORI, Kikuo YASUDA

Author information

Toshimi SEKI
Takayuki TAKEZAKI
Rikio OHUCHI
Hiroshi OHUYABU
Yoshitaka TANIMOTO
Takashi YAMAGUCHI
Norinobu SAITOH
Tsutomu ISHIMORI
Kikuo YASUDA
Author's Organization：
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,
Research Division, Teikoku Hormone Manufacturing Co., Ltd.,

Keywords: phenoxypropanolamine, hydrazinopyridazine, antihypertensive agent, hypotensive activity, β-blocking activity, β₁ selectivity

JOURNAL FREE ACCESS

1995 Volume 43 Issue 2 Pages 247-255

DOI https://doi.org/10.1248/cpb.43.247

Details

Abstract

A series of phenoxypropanolamines having a hydrazinopyridazinyl moiety was synthesized. Their hypotensive and β-blocking activities were evaluated after intravenous administration of the compounds to anethetized rats.Some of them exhibited both activities. In particular, compound 20k is a candidate for clinical use due to its hypotensive activity, equal to that of hydralazine, and its β-blocking activity, 2.7-fold more potent than that of propranolol.

Corresponding author

Register with J-STAGE for free!